Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) major shareholder Movers Lab Fund I. Lp Prime sold 22,757 shares of the business’s stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $2.33, for a total transaction of $53,023.81. Following the completion of the sale, the insider now directly owns 9,476,917 shares in the company, valued at approximately $22,081,216.61. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Vaxxinity Stock Performance
Vaxxinity stock traded down $0.04 on Thursday, hitting $2.34. The company’s stock had a trading volume of 119,635 shares, compared to its average volume of 579,544. The firm has a market cap of $294.90 million and a P/E ratio of -1.53. The company has a quick ratio of 4.17, a current ratio of 4.17 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average price of $1.97 and a 200-day moving average price of $3.55. Vaxxinity, Inc. has a one year low of $1.51 and a one year high of $22.77.
Institutional Investors Weigh In On Vaxxinity
Large investors have recently made changes to their positions in the company. Hollencrest Capital Management bought a new stake in shares of Vaxxinity in the 2nd quarter worth about $31,000. Clarius Group LLC bought a new stake in shares of Vaxxinity in the 2nd quarter worth about $31,000. Truist Financial Corp bought a new stake in shares of Vaxxinity in the 2nd quarter worth about $33,000. Bank of America Corp DE grew its holdings in shares of Vaxxinity by 7,829.0% in the 1st quarter. Bank of America Corp DE now owns 15,858 shares of the company’s stock worth $68,000 after purchasing an additional 15,658 shares during the last quarter. Finally, ETF Managers Group LLC bought a new stake in shares of Vaxxinity in the 4th quarter worth about $211,000. Institutional investors own 15.82% of the company’s stock.
Analysts Set New Price Targets
Ad Tradewins
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Separately, Evercore ISI assumed coverage on shares of Vaxxinity in a report on Wednesday, April 27th. They issued an “in-line” rating on the stock.
About Vaxxinity
Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer’s disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vaxxinity, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Vaxxinity wasn’t on the list.
While Vaxxinity currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Vaxxinity, Inc. (NASDAQ:VAXX) Major Shareholder Movers Lab Fund I. Lp Prime Sells 22,757